To hear about similar clinical trials, please enter your email below
Trial Title:
DP303c in Patients With HER2-positive Advanced Breast Cancer
NCT ID:
NCT05901935
Condition:
HER2-positive Advanced Breast Cancer
Conditions: Official terms:
Breast Neoplasms
Capecitabine
Trastuzumab
Vinorelbine
Study type:
Interventional
Study phase:
Phase 3
Overall status:
Not yet recruiting
Study design:
Allocation:
Randomized
Intervention model:
Parallel Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
DP303c
Description:
DP303c injection, 3.0 mg/kg, Q3W.
Arm group label:
DP303c
Intervention type:
Drug
Intervention name:
Trastuzumab
Description:
IV, 6 mg/kg, D1, Q3W
Arm group label:
Trastuzumab combined with vinorelbine/capecitabine
Intervention type:
Drug
Intervention name:
Vinorelbine Tartrate
Description:
IV, 25 mg/m^2，D1、D8，Q3W
Arm group label:
Trastuzumab combined with vinorelbine/capecitabine
Intervention type:
Drug
Intervention name:
Capecitabine tablets
Description:
PO 1000 mg/m^2, bid, D1-D14, Q3W
Arm group label:
Trastuzumab combined with vinorelbine/capecitabine
Summary:
This is a study of DP303c in patients with HER2-positive advanced breast cancer.
Detailed description:
This is a multi-centre, randomized, open-label, controlled phase Ш clinical study to
evaluate the efficacy and safety of DP303c injection versus trastuzumab combined with
vinorelbine/capecitabine in the treatment of HER2-positive advanced breast cancer.
Patients will be treated with DP303c injection at 3.0 mg/kg or trastuzumab combined with
vinorelbine/capecitabine every 3 weeks. Patients will continue to receive treatment until
disease progression, intolerable toxicity, withdrawal of informed consent, death, or any
other reasons for treatment discontinuation, whichever occurs first.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
1. Voluntarily agree to participate in the study and sign the informed consent;
2. Age≥18 years old;
3. Patients with unresectable locally advanced or metastatic breast cancer confirmed by
histology or cytology;
4. Confirmed to be HER2 positive by central lab (HER2-positive is defined as IHC 3+ or
IHC 2+ with ISH positive);
5. Received at least 2 lines of systemic therapy for unresectable locally advanced,
recurrent, or metastatic diseases;
6. Radiographic evidence of disease progression confirmed by the investigator during or
after the most recent systemic treatment;
7. At least one assessable lesion at the baseline;
8. The Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
9. Patients with adequate organ function;
10. Life expectancy ≥ 12 weeks;
11. Female and male patient of childbearing age must agree to take adequate
contraceptive measures during the entire study period.
Exclusion Criteria:
1. Pregnant or breastfeeding women;
2. History of any other malignant tumors within three years
3. Has not recovered from adverse reactions caused by previous anti-tumor treatments to
≤ grade 1 or baseline (refer to NCI CTCAE 5.0);
4. The presence of active inflammatory bowel disease, chronic diarrhoea, short bowel
syndrome or history of other gastrointestinal diseases or treatments that may affect
intestinal absorption;
5. Received systemic anti-tumor therapy within 28 days before randomization,
traditional Chinese medicine treatment with tumor indications approved by the
National Medical Administration (NMPA) and palliative radiotherapy within 2 weeks
before randomization;
6. Major organ surgery (excluding needle biopsy) within 28 days before randomization;
7. The cumulative amount of previous exposure to anthracyclines has reached the dosage;
8. Untreated (including baseline findings) or unstable cerebral parenchymal metastasis,
spinal cord metastasis or compression, and cancerous meningitis.
9. History of LVEF < 40%, symptomatic congestive heart failure (CHF),.
10. Serious or uncontrolled cardiovascular disease;
11. History of (non-infectious) interstitial lung disease/pneumonitis requiring steroid
hormone therapy;
12. Patients who currently have corneal diseases that require medication or surgical
intervention;
13. Peripheral neuropathy ≥ grade 3 (refer to NCI CTCAE 5.0);
14. Active infections requiring intravenous antibiotics, antivirals, or antifungals
within 2 weeks before randomization;
15. Active hepatitis B or C;
16. History of immunodeficiency diseases, including human immunodeficiency virus (HIV)
positive;
17. Known hypersensitivity or contraindication to the active ingredients or excipients
of the study drugs;
18. Treated with strong CYP3A inhibitors or strong CYP3A inducers before randomization;
19. There are other circumstances that may interfere with the subject's participation in
the study procedures or do not meet the subject's maximum benefit from participating
in the study or affect the study results.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Start date:
July 2023
Completion date:
July 2028
Lead sponsor:
Agency:
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Agency class:
Industry
Source:
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05901935
